| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Necrostatin-5 manufacturers
- Necrostatin-5
-
-
2026-08-21
- CAS:337349-54-9
- Purity: 99.40%
- Supply Ability: 10g
|
| | Necrostatin-5 Basic information |
| Product Name: | Necrostatin-5 | | Synonyms: | Necrostatin-5;Necrostatin-5 (Nec-5);2-[[3,4,5,6,7,8-Hexahydro-3-(4-methoxyphenyl)-4-oxo[1]benzothieno[2,3-d]pyrimidin-2-yl]thio]-acetonitrile;3-p-methoxyphenyl-5,6-tetramethylenothieno[2,3-d]pyrimidin-4-one-2-mercaptoethylcyanide;Acetonitrile, 2-[[3,4,5,6,7,8-hexahydro-3-(4-methoxyphenyl)-4-oxo[1]benzothieno[2,3-d]pyrimidin-2-yl]thio]-;Necrostatin-5 >=98% (HPLC), solid;Necrostatin5,Necrostatin 5;2-((3-(4-Methoxyphenyl)-4-oxo-3,4,5,6,7,8-hexahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)thio)acetonitrile | | CAS: | 337349-54-9 | | MF: | C19H17N3O2S2 | | MW: | 383.49 | | EINECS: | | | Product Categories: | | | Mol File: | 337349-54-9.mol |  |
| | Necrostatin-5 Chemical Properties |
| Melting point | 212-214℃ | | storage temp. | 2-8°C | | solubility | DMSO: >10mg/mL | | form | solid | | color | white to off-white | | InChI | 1S/C19H17N3O2S2/c1-24-13-8-6-12(7-9-13)22-18(23)16-14-4-2-3-5-15(14)26-17(16)21-19(22)25-11-10-20/h6-9H,2-5,11H2,1H3 | | InChIKey | VGONMECBFMCKBS-UHFFFAOYSA-N | | SMILES | COc1ccc(cc1)N2C(=O)c3c4CCCCc4sc3N=C2SCC#N |
| Hazard Codes | Xi | | Risk Statements | 36 | | Safety Statements | 26 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Chronic 4
Eye Irrit. 2 |
| | Necrostatin-5 Usage And Synthesis |
| Uses | Necrostatin-5 (Nec-5) is a potent necroptosis inhibitor with an EC50 value of 0.24 μM. Necrostatin-5 also is a RIP1 inhibitor. Necrostatin-5 shows cardioprotective effects[1][2][3]. | | Biological Activity | Necrostatin-5 is an inhibitor of necroptosis (non-apoptotic cell death pathway) by indirect inhibition of RIP1 kinase. Necroptosis is defined as alternative active cell death pathway: Death-Domain Receptor (DRs, e.g. Fas/TNFR) mediated and caspase-inhibitor insensitive with specific morphology (nuclear condensation, organelle swelling, loss of plasma membrane integrity). The necrostatins have been discovered to inhibit this pathway by inhibition of the death domain receptor-associated adaptor kinase RIP1. Three distinct mechanisms appear to be involved: T-loop dependent inhibition by necrostatin-1; partially T-loop independent inhibition by necrostatin-3 and indirect inhibition of RIP1 by necrostatin-5, since necrostatin-5 is a potent inhibitor of immunnoprecipitated RIP1, but does not inhibit recombinant RIP1. | | in vivo | Necrostatin-5 (2.46 mg/kg; i.p.) shows cardioprotective effects on the isolated heart model in rats[2]. | Animal Model: | 200-300 g, male Wistar rats[2] | | Dosage: | 2.46 mg/kg | | Administration: | I.p.; 60 min before experiment | | Result: | Reduced the infarction zone caused by 30-min global ischemia and 120-min reperfusion. |
| | IC 50 | RIPK1; necroptosis: 0.24 μM (EC50) | | storage | +4°C | | References | [1] Wang K, et al. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1455-65. DOI:10.1016/j.bmcl.2006.11.056
[2] Dmitriev YV, et al. Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion. Bull Exp Biol Med. 2013 Jun;155(2):245-8. DOI:10.1007/s10517-013-2124-2
[3] González-Juarbe N, et al. Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia. PLoS Pathog. 2015 Dec 11;11(12):e1005337. DOI:10.1371/journal.ppat.1005337 |
| | Necrostatin-5 Preparation Products And Raw materials |
|